You’ve been in therapy for months. You’ve tried multiple medications at therapeutic doses. You’ve done the exposure exercises, faced your fears, and followed your treatment plan diligently. Yet your OCD symptoms still significantly impact your daily life. If this describes your experience, you’re facing what clinicians call treatment-resistant OCD—and you’re far from alone. Research shows that only up to 50% of people with OCD respond adequately to first-line SSRI medications (Ruscio et al., 2023). This doesn’t mean you’re out of options. It means it’s time to explore a broader range of evidence-based interventions that go beyond the standard initial approaches. Understanding what treatment resistance means and what pathways exist beyond it can help you make informed decisions about your next steps.
Understanding What Treatment Resistance Really Means
The term “treatment-resistant” can feel discouraging, but it’s simply a clinical descriptor, not a judgment about your effort or prognosis.
In OCD treatment, resistance typically refers to an inadequate response after trying at least two different evidence-based treatments for sufficient duration and at appropriate doses. The International Treatment Refractory OCD Consortium defines treatment response as a 35% or greater reduction in Yale-Brown Obsessive Compulsive Scale (YBOCS) scores (Ruscio et al., 2023). Anything less than a 25% reduction is considered non-response.
What’s important to understand is that treatment resistance doesn’t mean treatment failure. It means your OCD requires a more sophisticated approach than the initial strategies. Your brain’s particular wiring, your symptom presentation, or factors like comorbid conditions may require interventions that target different neural pathways or use different mechanisms of action.
The reality is that OCD is a heterogeneous disorder. Two people with the same diagnosis might have completely different symptom presentations, different underlying brain circuit dysfunctions, and therefore different treatment needs. What works remarkably well for one person may not work for another—not because either person is doing something wrong, but because their OCD operates differently at a neurobiological level.
Why Standard Treatments Sometimes Fall Short
Before exploring what comes next, it’s worth understanding why first-line treatments don’t work for everyone.
SSRIs—the most commonly prescribed medications for OCD—work by increasing serotonin availability in the brain. For many people, this helps reduce the intensity and frequency of obsessive thoughts and the urge to perform compulsions. But serotonin is just one piece of a complex neurochemical puzzle. OCD involves dysfunction in multiple brain circuits and neurotransmitter systems, including glutamate, dopamine, and the connections between the prefrontal cortex, anterior cingulate cortex, and striatum.
Similarly, cognitive behavioral therapy with exposure and response prevention (ERP) is highly effective for many people with OCD. It works by helping your brain learn that the feared outcome doesn’t occur when you resist compulsions. But if your anxiety is so severe that you can’t engage with exposures, if you have poor insight into your symptoms, or if other factors interfere with the learning process, ERP alone may not provide sufficient relief.
Sometimes what appears to be treatment resistance is actually inadequate treatment. A medication dose that’s too low, therapy that doesn’t include proper exposure components, or insufficient duration of treatment can all look like resistance when the issue is actually implementation. This is why comprehensive psychiatric evaluation matters—distinguishing between true treatment resistance and optimization opportunities.
At Catalyst Psychiatry in Corvallis, this distinction is central to the diagnostic process. Since establishing the practice in 2014, the focus has been on accurate, ongoing assessment rather than quick fixes. Dr. Jennifer Hamilton, a Stanford-trained board-certified psychiatrist with over 20 years of experience, emphasizes that diagnosis and treatment planning are evolving processes that require collaboration and careful attention to what’s actually happening with each individual.
Optimizing Your Current Treatment Approach
If your current treatments aren’t working well, the first step is often optimization rather than abandonment.
This might mean increasing medication dosages to therapeutic levels—which for OCD are often higher than doses used for depression or anxiety. It might mean extending the trial duration, as OCD symptoms can take 10-12 weeks to respond to medication rather than the 4-6 weeks typical for depression. It could involve adding specific augmentation strategies that have evidence behind them.
For therapy, optimization might mean intensifying the frequency of sessions, working with a specialist who has specific expertise in OCD and ERP, or addressing factors that might be interfering with your ability to engage with treatment. Sometimes untreated depression, substance use, or significant life stressors need to be addressed before OCD treatment can be fully effective.
Medication augmentation is a common next step when SSRIs provide partial but insufficient benefit. Low-dose atypical antipsychotics like aripiprazole or risperidone have strong evidence supporting their use as augmentation agents in OCD. These medications affect dopamine pathways that interact with the serotonin systems involved in OCD, potentially providing additional symptom relief when added to an SSRI.
Genetic testing through services like GeneSight can also inform medication decisions at this stage. These pharmacogenetic tests analyze how your genes affect medication metabolism and can help identify which medications you’re more likely to respond to and which might cause more side effects. While not definitive, this information can guide more personalized medication selection.
When Brain Stimulation Becomes an Option
For individuals who haven’t achieved adequate relief through medication optimization and intensive therapy, neuromodulation treatments offer a different approach entirely.
Deep transcranial magnetic stimulation (Deep TMS) received FDA clearance for OCD treatment in 2018 based on robust clinical evidence. A multicenter randomized controlled trial found that 38% of patients receiving active Deep TMS achieved clinical response (defined as 30% or greater reduction in symptoms) compared to only 11% receiving sham treatment (Carmi et al., 2019). Subsequent real-world data from 22 clinical sites showed even higher response rates, with 52.4% of patients achieving sustained response.
Deep TMS works by using magnetic fields to stimulate specific brain regions involved in OCD—particularly the medial prefrontal cortex and anterior cingulate cortex. These are areas where research has identified dysfunction in the brain circuits that drive obsessive thoughts and compulsive behaviors. The treatment doesn’t require surgery, doesn’t involve medications, and allows people to return to normal activities immediately after each session.
Treatment typically involves daily sessions over several weeks. Most people begin noticing improvement within the first 20 sessions, though results vary by individual. The magnetic stimulation is paired with brief symptom provocation—thinking about your OCD triggers—which helps activate the relevant brain networks during treatment.
Catalyst Psychiatry is the only provider of Deep TMS in the mid- Willamette Valley, making this advanced treatment option accessible to individuals throughout the Corvallis area and surrounding communities.
It’s important to understand that Deep TMS isn’t effective for everyone—no treatment is. But for individuals who meet the criteria (typically having tried at least two adequate medication trials or one medication plus therapy), it represents a scientifically validated option that works through a completely different mechanism than conventional treatments.
Exploring Novel Medication Approaches
Beyond standard SSRIs and augmentation with antipsychotics, researchers have identified other medication pathways worth considering for treatment-resistant cases.
Medications that modulate glutamate—the brain’s primary excitatory neurotransmitter—have shown promise in treatment-resistant OCD. N-acetylcysteine (NAC), an over-the-counter supplement with glutamate-modulating properties, has demonstrated benefit in some studies. Memantine, an NMDA receptor antagonist approved for Alzheimer’s disease, has also been studied as an augmentation agent with mixed but sometimes positive results.
For individuals with treatment-resistant depression that co-occurs with OCD, SPRAVATO® (esketamine) nasal spray represents another glutamate-focused approach. While specifically approved for treatment-resistant depression rather than OCD, esketamine monotherapy demonstrated statistically significant improvement compared to placebo, with rapid effects visible as early as 24 hours after the first dose (Janik et al., 2025). The medication works through NMDA receptor antagonism, affecting glutamate pathways in ways that differ fundamentally from traditional antidepressants.
SPRAVATO® is administered in a clinical setting under medical supervision, as it can cause temporary side effects including dissociation and sedation. Patients remain at the clinic for at least two hours after administration to ensure safety. When depression significantly complicates OCD treatment, addressing the depression with novel approaches can sometimes create the conditions for more effective OCD treatment.
Catalyst Psychiatry offers both Deep TMS and SPRAVATO® treatment, currently accepting new patients specifically for these advanced interventions. This reflects the practice’s commitment to providing access to cutting-edge, evidence-based treatments for individuals who haven’t found adequate relief through conventional approaches.
Intensive and Specialized Treatment Programs
Sometimes the intensity or specialization of treatment needs to change rather than the type of treatment.
Intensive outpatient programs (IOPs) for OCD provide multiple therapy sessions per week, often incorporating both individual and group components. This format allows for more rapid progress with exposure exercises and provides the structure that some people need to make meaningful gains. While Catalyst Psychiatry doesn’t operate an IOP, they can provide referrals to specialized programs when this level of care would benefit a patient.
Residential treatment programs offer even more intensive intervention for severe, treatment-resistant OCD. These programs typically involve weeks or months of comprehensive treatment in a structured environment. They’re not necessary or appropriate for most people with treatment-resistant OCD, but for individuals whose symptoms have become completely debilitating, they can provide a reset that outpatient treatment hasn’t achieved.
The key is matching treatment intensity to symptom severity and treatment response. This requires honest assessment of what’s working, what isn’t, and what level of intervention is truly needed rather than continuing with an approach that isn’t producing adequate results.
Addressing Complicating Factors
Treatment resistance sometimes stems not from the OCD itself being especially difficult, but from other factors that interfere with treatment effectiveness.
Undiagnosed or undertreated ADHD can make it difficult to stick with exposure exercises or medication schedules. Substance use—including daily alcohol or cannabis—can interfere with both medication effectiveness and the brain’s ability to form new learning patterns during therapy. Trauma history may require specific therapeutic approaches before standard OCD treatment can gain traction.
Sleep disorders, chronic pain, relationship dysfunction, ongoing high stress—all of these can maintain OCD symptoms or prevent treatment from working as well as it otherwise might. A comprehensive approach looks at the whole person and their circumstances, not just the OCD symptoms in isolation.
This is where Catalyst Psychiatry’s philosophy of holistic care becomes particularly relevant. The practice emphasizes coordination with other healthcare providers—primary care physicians, specialists, other therapists—to ensure that all factors affecting mental health are being addressed. They encourage complementary approaches including exercise, good sleep hygiene, and stress management techniques alongside psychiatric treatment.
Making Decisions About Next Steps
Navigating treatment-resistant OCD requires partnership with clinicians who understand both the complexity of the disorder and the range of evidence-based options available.
Consider whether you’ve truly optimized your current treatment. Are you taking medications at the highest therapeutic doses? Have you engaged with properly structured ERP from a therapist with specific OCD expertise? Have you given treatments adequate time to work? Sometimes what looks like resistance is actually incomplete implementation.
If optimization has been thorough and you’re still struggling, it’s time to explore advanced options. This means having detailed conversations about things like Deep TMS, medication augmentation strategies, or evaluation for comorbid conditions that might be interfering with treatment.
Cost and insurance coverage are practical considerations that matter. Most major insurance plans cover various treatment options, though coverage specifics vary. Catalyst Psychiatry accepts most major insurance providers (though not Medicare, Medicare Advantage plans, or Oregon Health Plan) and can help you understand what your insurance covers. For advanced treatments like Deep TMS, insurance often requires documentation that standard treatments have been tried first.
The scheduling commitment also varies by treatment type. Deep TMS requires daily visits for several weeks. Traditional medication management might require monthly appointments. Consider what you can realistically commit to, as consistent engagement is necessary for any treatment to work.
What Success Looks Like With Treatment-Resistant OCD
It’s important to calibrate expectations appropriately when dealing with treatment-resistant OCD.
Success might not mean complete elimination of symptoms. For many people with treatment-resistant OCD, meaningful success means reducing symptoms enough that they can work, maintain relationships, and engage in activities they value—even if some symptoms persist. It means spending an hour on rituals instead of six hours, or experiencing intrusive thoughts occasionally instead of constantly.
The International Treatment Refractory OCD Consortium considers a 35% reduction in symptom severity a full response. While that might sound modest, for someone who has been severely impaired by OCD, a 35% reduction can mean the difference between being unable to leave the house and being able to hold a job.
Results vary by individual—this reality cannot be overstated. Some people experience dramatic improvement with advanced treatments. Others see moderate gains. A smaller percentage see minimal change. The goal is finding the approach that provides enough relief for you to reclaim meaningful aspects of your life, even if perfect symptom resolution remains elusive.
Moving Forward From Here
If you’re reading this because standard OCD treatments haven’t provided adequate relief, the most important thing to understand is that additional options exist.
Treatment resistance doesn’t mean you’re stuck with your current level of symptoms forever. It means you need a more sophisticated treatment plan, possibly involving interventions that target different brain systems or use different therapeutic mechanisms than what you’ve tried so far.
Start by ensuring you’ve truly optimized your current treatments. Work with a psychiatrist who can evaluate whether dose adjustments, augmentation strategies, or addressing complicating factors might improve your response to existing treatments. If optimization has been thorough and you’re still struggling significantly, it’s time to explore advanced options like Deep TMS or novel medication approaches.
At Catalyst Psychiatry, comprehensive evaluation and accurate diagnosis form the foundation of treatment planning, especially for complex cases. The practice’s emphasis on evidence-based treatments, patient-centered collaboration, and willingness to offer advanced interventions like Deep TMS and SPRAVATO® reflects an understanding that treatment-resistant OCD requires more than standard approaches.
You can reach Catalyst Psychiatry at (541) 730-4400 to discuss whether advanced treatment options might be appropriate for your situation. The practice is currently accepting new patients specifically for Deep TMS and SPRAVATO® treatments.
Living with treatment-resistant OCD is exhausting and discouraging. But resistance to initial treatments doesn’t define your long-term prognosis. With comprehensive evaluation, thoughtful treatment planning, and access to the full range of evidence-based interventions, meaningful improvement remains possible even when standard approaches have fallen short.
References
If you’re experiencing a mental health crisis, call 988 for the Suicide & Crisis Lifeline. For questions about treatment-resistant OCD in Corvallis, contact Catalyst Psychiatry at (541) 730-4400.